Original Research Article

Prevalence of thyroid dysfunction in metabolic syndrome - A cross-sectional study

Shravya R Ginnaram¹, D Sridevi¹*, Amrut Arvindrao Dambal¹, Sushritha Y Reddy¹, Abhinav R Pingle¹

¹Dept. of Biochemistry, Malla Reddy Institute of Medical Sciences, Hyderabad, Telangana, India

A R T I C L E   I N F O

Article history:
Received 16-04-2020
Accepted 03-06-2020
Available online 28-09-2020

Keywords:
Metabolic Syndrome(MetS)
Cardiovascular Disease(CVD)
Type 2 Diabetes Mellitus (T2DM)
Subclinical Hypothyroidism (SCH)
Thyroid Stimulating Hormone (TSH)
Thyroxine (T4)
Triiodothyronine(T3)

A B S T R A C T

Background and Objectives: Literature review have hypothesized that the rising incidence of metabolic syndrome worldwide has been associated with an increased risk of thyroid disorders. The aim & objective of our study was to diagnose patients with metabolic syndrome based on IDF criteria, to estimate T3, T4, TSH levels among these patients and to observe the correlation between thyroid dysfunction and metabolic syndrome.

Materials and Methods: Our study was a hospital based age and sex matched cross-sectional study with a total of 120 participants (60 cases and 60 controls) between 30 - 50 years old conducted at Malla Reddy Institute of Medical Sciences, Hyderabad, India. Ethics approval was obtained from the Institutional Ethics Committee.

Results: Our study found that both men and women with metabolic syndrome had a higher percentage of thyroid disorders compared to the controls without metabolic syndrome. Among the cases, women were found to present with more thyroid abnormalities than men.

Conclusion: Routine screening with thyroid function tests should be implemented for all patients with metabolic syndrome, especially females. The coexistence of these two entities can increase the risk for cardiovascular disease. Early detection and intervention can help reduce the progression of CVD.

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/)

1. Introduction

Metabolic Syndrome (MetS) is a constellation of risk factors that as a group have a greater predictive ability for disease than when considered separately, which may be indicative of future cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in adults.¹

They include: central obesity, elevated triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C), raised blood pressure (BP) and raised fasting blood glucose. The presence of three or more of these risk factors indicates MetS. It is also associated with pro-thrombotic and pro-inflammatory states.²

Insulin resistance is a central component of metabolic syndrome.³ Increasing body fat, especially visceral fat, is also associated with an increase in the prevalence of metabolic syndrome.

The ongoing epidemic of obesity appears to have affected all sectors of the population over the past several years due to increased calorie consumption and sedentary lifestyles.⁴,⁵ Increasing rates of obesity are proportional to the increase in the prevalence of T2DM, CVD, high blood pressure, sleep apnea, and certain cancers.⁶

Thyroid hormones have a profound effect on energy homeostasis, fatty acid and glucose metabolism and blood pressure.⁷ Therefore, there is a probability that functional changes in the thyroid gland might have an association with MetS and its related components.⁸ Thyroid-stimulating hormone (TSH) directly correlates with insulin resistance, TG and indirectly with HDL-C.⁹

Hypothyroidism is characterized by elevated levels of TSH with decreased levels of T3 and T4.
Subclinical hypothyroidism (SCH), characterized by elevated TSH levels with normal levels of T3 and T4, is more common than overt hypothyroidism with a prevalence of 1.4–7.8% in asymptomatic older individuals and even greater percentiles among women.10

Hyperthyroidism is characterized by decreased levels of TSH with elevated levels of T3 and T4. Subclinical hyperthyroidism (SCH) is characterized by decreased levels of TSH with normal levels of T3 and T4.

The current study aims to investigate the prevalence of thyroid dysfunction in metabolic syndrome and to study the association between thyroid disorders and the components of metabolic syndrome.

2. Materials and Methods

This study was taken up in Malla Reddy Institute of Medical Sciences, Hyderabad, India. Ethical clearance was obtained from the Institutional ethics committee. This was a hospital based cross-sectional study with a total of 120 age and sex matched subjects (60 cases and 60 controls) between 30-50 years old were selected from the outpatient departments of General Medicine and Obstetrics and Gynecology. The study was conducted between May - August 2015. Detailed proper informed consent was taken from all the subjects.

2.1. Inclusion criteria (Based on IDF definition)

After proper physical and biochemical analysis of the subjects the following were the criteria for inclusion:

Central adiposity (Waist circumference ≥ 90 cm in males and ≥ 80 cm in females) plus two or more of the following four factors:

1. Serum Triglycerides: ≥150mg/dl
2. Serum HDL cholesterol: <40 mg/dl in men and <50 mg/dl in women
3. Blood pressure: Systolic Blood Pressure ≥ 130 mmHg or Diastolic Blood Pressure ≥85 mmHg
4. Fasting plasma glucose concentration of ≥100 mg/dl.

2.1.1. Cases

Subjects fulfilling the criteria for MetS were included as cases.

2.1.2. Controls

Apparent normal and healthy subjects without MetS were considered as controls.

2.2. Exclusion criteria

1. Subjects under treatment for thyroid disorders, dyslipidemia.
2. Patients on drugs which alters glucose and thyroid hormone metabolism like steroids, antipsychotics
3. Pregnancy.

4. Significant hepatic, renal or cardiovascular disease.

2.3. Anthropometry

Waist circumference was measured at the midpoint between the lower margin of the lowest palpable rib and the top of the iliac crest, at the end of a normal expiration using a non-stretchable fiber measure tape, with the tape held parallel to the floor.

After a period of 15 minutes rest, blood pressure (BP) was measured as SBP and DBP in the right upper limb with the help of a sphygmomanometer in the supine position, placing the sphygmomanometer at the level of the heart.

2.4. Biochemical tests

Fasting morning blood samples (5ml) were collected by anterior cubital vein venipuncture in a plain red top vacutainer for separation of serum. The sample was set aside for 15 minutes to clot. The specimens were centrifuged to separate the serum and analyzed. Fasting glucose was determined by the GOD-POD method.

Serum cholesterol was detected by the enzymatic CHOD/POD method. Serum HDL-C was estimated by direct method.11 Serum triglyceride was estimated by Glycerol Phosphate Oxidase/Peroxidase (GPO/POD) colorimetric endpoint method. LDL-C was obtained using Friedwald’s formula as given below:

$$LDL-C = \text{Total cholesterol} - (\text{HDL-C} + \text{VLDL-C})$$

TSH, Total T3 and Total T4: were estimated by Chemiluminescence immunoassay (CLIA) using neolumax.

2.5. Statistical methods

Data was analyzed by applying appropriate statistical tests by using SPSS package version number 20.

Data was expressed in terms of mean ± SD. Student’s ‘t’ test was applied to estimate the difference between the two groups of the population. P value < 0.05 was taken as significant.

3. Results

A hospital based cross-sectional study was carried out to study the prevalence of thyroid dysfunction among males and females with and without metabolic syndrome.

Mean WC in male controls was 87.17 ± 1.82 compared to cases with 103.13 ± 6.46 displaying a highly significant statistical difference (p < 0.0001). Mean WC in female controls was 78.23 ±4.39 compared to cases with 94.07 ± 8.22 displaying highly significant statistical difference (p < 0.0001) (Tables 1 and 2).

Mean SBP in male controls was 121.20 ± 7.92 compared to cases with 127.80 ± 10.91 displaying a significant statistical difference (p=0.0095). Mean SBP in female controls was 114.60 ± 9.88 compared to cases with...
123.93 ± 15.80 displaying a significant statistical difference (p=0.0081). (Tables 1 and 2).

Mean DBP in male controls was 78.73 ± 6.40 compared to cases with 84.0 ± 8.98 displaying a significant statistical difference (p =0.0011). Mean DBP in female controls was 74.07 ± 8.62 compared to cases with 81.20 ± 9.54 displaying a significant statistical difference (p =0.0036). (Tables 1 and 2).

Mean FPG in male controls was 95.23 ± 12.71 compared to cases with 113.03 ± 18.61 displaying a highly significant statistical difference (p <0.0001). Mean FPG in female controls was 92.90 ±8.66 compared to cases with 107.67 ± 14.89 displaying a highly significant statistical difference (p < 0.0001). (Tables 1 and 2).

Mean TG in male controls was 126.50 ± 49.10 compared to cases with 180.97 ± 91.18 displaying a significant statistical difference (p =0.0056). Mean TG in female controls was 103.03 ±28.83 compared to cases with 158.23 ± 86.85 displaying a significant statistical difference (p =0.0016). (Tables 1 and 2).

Mean HDL in male controls was 40.60 ± 6.01 compared to cases with 37.07 ± 4.18 displaying a significant statistical difference (p = 0.0106). Mean HDL-C in female controls was 47.73 ± 8.16 compared to cases with 41.30 ± 6.83 displaying a significant statistical difference (p = 0.0016). (Tables 1 and 2).

Mean T3 in male controls was 1.09 ± 0.25 compared to cases with 1.02 ± 0.28 and is not significant (p = 0.3542). Mean T3 in female controls was 1.51 ±1.78 compared to cases with 1.06 ±0.27 and is not significant (p = 0.1739). (Tables 1 and 2).

Mean T4 in male controls was 9.12 ± 1.93 compared to cases with 8.82 ±2.54 and is not significant (p =0.6104). Mean T4 in female controls was 9.61 ±1.53 compared to cases with 9.51 ± 2.05 and is not significant (p =0.8218). (Tables 1 and 2).

Mean TSH in male controls was 2.18 ± 1.21 compared to cases with 3.89 ±3.75 displaying a significant statistical difference (p =0.0209). Mean TSH in female controls was 2.76 ±1.52 compared to cases with 6.44 ± 9.14 displaying a significant statistical difference (p =0.0339). (Tables 1 and 2).

4. Discussion

In this study, we found that 16.7% among male metabolic syndrome patients (overt hypothyroidism 3.3% and subclinical hypothyroidism 13.33%) and 30% among female metabolic syndrome patients (overt hypothyroidism 6.66% and subclinical hypothyroidism 23.33%) exhibited thyroid dysfunction. In the control group, 3.33% males and 6.66% females had subclinical hypothyroidism. In a recent population-based study among the adult population in India, the prevalence of hypothyroidism was 3.9% while that of subclinical hypothyroidism was 9.4%. 

According to the report by Shantha et al., the prevalence of overt hypothyroidism was 7.4% and that of subclinical hypothyroidism was 21.9% in the MetS population. 

In this study, the prevalence of thyroid dysfunction was more in females compared to males, comparable to the study by Uzunulu et al. Therefore, we recommend the routine screening of thyroid function in patients with MetS, particularly among females.

This study showed a significant association of thyroid dysfunction with MetS in both males and females (P = 0.004). A significant difference was found in the mean values for each anthropometric and biochemical parameters among patients with MetS and healthy control subjects; only T3 and T4 were not significantly altered. Thus, thyroid dysfunction was found to be related to all the components of MetS. These findings were similar to those obtained by Kota et al., who mentioned body mass index (BMI), WC, mean systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), total cholesterol, low density lipoprotein cholesterol (LDL-C), TG, and TSH were significantly higher in the MetS group compared to the control group and HDL-C was significantly lower in the study group. Similar findings were found in the study conducted by Meher et al.

We found no correlation between TSH and all the components of MetS in our study. The study by Wang et al. showed no statistical correlation between subclinical thyroid disease and MetS, in contrast to the significant correlation reported in the study by Kim et al. In this study, we did not find any case of hyperthyroidism in contrast to the work done by Jayakumar.

Both systolic and diastolic blood pressure were found to be significantly increased in subclinical hypothyroid women. TSH levels were found to have a positive correlation with blood pressure. In a large population study, a positive linear association was established between systolic and diastolic arterial pressure and TSH levels. Reduced thyroid function can increase peripheral vascular resistance and activate the sympatho-adrenal system, increasing the BP, particularly DBP.

Insulin resistance is the key pathologic factor for the progression of metabolic syndrome and is the cardinal promotive factor for T2DM, dyslipidemia and thyroid dysfunction proven by the study conducted by Singh BM et al, who concluded that there was a significant correlation between TSH and insulin. Bakker et al. demonstrated interactions between insulin resistance and thyroid function in euthyroid non diabetic adults. Their observations stated that insulin resistance increases the deleterious effect of hypothyroidism on lipid profile reflecting the association of insulin resistance with low serum HDL-C and increased TGs.

Serum levels of TSH are a reliable index of the biological activity of thyroid hormones. Some studies
### Table 1: Comparative study of male cases with controls

| Parameters   | Controls | Cases       | P Value  | Significance     |
|--------------|----------|-------------|----------|------------------|
|              | MEAN     | SD±         | MEAN     | SD±              |                |
| WC(cm)       | 87.17    | 1.82        | 103.13   | 6.46             | *<0.0001       |
| SBP(mm of Hg)| 121.20   | 7.92        | 127.80   | 10.91            | *0.0095        |
| DBP(mm of Hg)| 78.73    | 6.40        | 84.0     | 8.98             | *0.0113        |
| FBS(mg/dl)   | 95.23    | 12.71       | 113.03   | 18.61            | *<0.0001       |
| TG(mg/dl)    | 126.50   | 49.10       | 180.97   | 91.18            | *0.0056        |
| HDL(mg/dl)   | 40.60    | 6.01        | 37.07    | 4.18             | *0.0106        |
| T3(ng/ml)    | 1.09     | 0.25        | 1.02     | 0.28             | 0.3542         |
| T4(μg/dl)    | 9.12     | 1.93        | 8.82     | 2.55             | 0.6104         |
| TSH (mIU/L)  | 2.18     | 1.21        | 3.89     | 3.75             | *0.0209        |

*p<0.05 is significant

### Table 2: Showing comparative study of female cases with controls

| Parameters   | Controls | Cases       | P Value  | Significance     |
|--------------|----------|-------------|----------|------------------|
|              | MEAN     | SD±         | MEAN     | SD±              |                |
| WC(cm)       | 78.23    | 4.39        | 94.07    | 8.22             | *<0.0001       |
| SBP(mm of Hg)| 114.60   | 9.88        | 123.93   | 15.80            | *0.0081        |
| DBP(mm of Hg)| 74.07    | 8.62        | 81.20    | 9.54             | *0.0036        |
| FBS(mg/dl)   | 92.90    | 8.66        | 107.67   | 14.89            | *<0.0001       |
| TG(mg/dl)    | 103.03   | 28.83       | 158.23   | 86.85            | *0.0016        |
| HDL(mg/dl)   | 47.73    | 8.16        | 41.30    | 6.83             | *0.0016        |
| T3(ng/ml)    | 1.51     | 1.78        | 1.06     | 0.27             | 0.1739         |
| T4 (μg/dl)   | 9.61     | 1.53        | 9.51     | 2.05             | 0.8218         |
| TSH (mIU/L)  | 2.76     | 1.52        | 6.44     | 9.14             | *0.0339        |

P <0.05 is significant

### Table 3: Prevalence of thyroid dysfunction in males

|                  | Cases | Controls | Total |
|------------------|-------|----------|-------|
| Thyroid dysfunction | 5     | 1        | 6     |
| Euthyroid        | 25    | 29       | 54    |
| Total            | 30    | 30       | 60    |

### Table 4: Prevalence of thyroid dysfunction in females

|                  | Cases | Controls | Total |
|------------------|-------|----------|-------|
| Thyroid dysfunction | 9     | 2        | 11    |
| Euthyroid        | 21    | 28       | 49    |
| Total            | 30    | 30       | 60    |

### Table 5: Prevalence of thyroid dysfunction in males and females combined

|                  | Cases | Controls | Total |
|------------------|-------|----------|-------|
| Thyroid dysfunction | 14    | 3        | 17    |
| Euthyroid        | 46    | 57       | 103   |
| Total            | 60    | 60       | 120   |
showed that adipocytes and preadipocytes expressed TSH receptors to which TSH would bind and induce preadipocytes to produce and release adipokines like leptin playing an important role in the onset of metabolic syndrome and cardiovascular disease.\textsuperscript{25} Leptin regulates TRH expression\textsuperscript{26} and insulin increases the total Leptin levels.\textsuperscript{27} Thus, increased abdominal fat along with insulin resistance may contribute to increased serum TSH levels via serum leptin concentrations.\textsuperscript{28} 

In conclusion, the prevalence of thyroid dysfunction, distinctively Subclinical Hypothyroidism in patients with MetS was found to be high with females being at an increased risk. Although thyroid hormones significantly affect each component of MetS, there was no relationship found between thyroid dysfunction and all of the components of MetS. There is an increased incidence of thyroid dysfunction, especially elevated TSH with normal T4 and T3 in MetS. Furthermore, the coexistence of the two disease entities might substantially increase the risk of Arterio Sclerotic Cardio Vascular Disease (ASCVD), hence it is worthwhile to order TSH and iT4 levels in all patients with MetS.

5. Source of Funding

ICMR.

6. Conflict(s) of Interest

Nil

7. Acknowledgement

We acknowledge ICMR for funding the study under ICMR STS project during the year 2015.

References

1. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, et al. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults. \textit{Circ}. 2004;110(10):1245–50.

2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel HR, Franklin BA. Diagnosis and management of the metabolic syndrome: an American heart association/ national heart, lung and blood institute scientific statement: executive summary. \textit{Circ}. 2005;112:285–90.

3. Reaven GM. Role of insulin resistance in human disease. \textit{Diabetes}. 1988;37:1595–1607.

4. Ogden CL, Curtin LR. Prevalence of overweight and obesity in the United States. \textit{JAMA}. 1999;285:1549–55.

5. Mehboob F, Majeed MZ, Zaman SM. An impact of lifestyle and obesity on diabetes, hypertension and hyperlipidemia. \textit{J Fatima Jinnah Med Coll Lahore}. 2007;1:59–63.

6. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of Overweight on the Risk of Developing Common Chronic Diseases During a 10-Year Period. \textit{Arch Intern Med}. 2001;161(13):1581–6.

7. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. \textit{Curr Hypertens Rep}. 2003;5(6):513–20.

8. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A. Wittenberg JC2000 Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. \textit{Ann Intern Med}. 2012;153:270–8.

9. Åsvold BO, Vatten LJ, Nilsen TIL, Bjørk T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. \textit{Eur J Endocrinol}. 2007;156(2):181–6.

10. Samuels MH. Subclinical thyroid disease in the elderly. \textit{Thyroid}. 1998;9:803–13.

11. Kimberly MM, Leary ET, Cole TG, Waymack PP. Selection, Validation, Standardization, and Performance of a Designated Comparison Method for HDL-Cholesterol for Use in the Cholesterol Reference Method Laboratory Network. \textit{Clin Chem}. 1999;45:1803–12.

12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. \textit{Clin Chem}. 1972;18(6):499–502.

13. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological perspective. \textit{Indian J Endocrinol Metab}. 2011;15(6):78–81.

14. Shantha G, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, et al. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. \textit{Thyroid Res}. 2009;2(1):2–2.

15. Uzunulu M, Yorulmaz E, Oguz A. Prevalence of Subclinical Hypothyroidism in Patients with Metabolic Syndrome. \textit{Endocr J}. 2007;54(1):71–6.

16. Kota SK, Meher LK, Krishna S, Modi K. Hypothyroidism in metabolic syndrome. \textit{Indian J Endocrinol Metab}. 2012;16(2):332–3.

17. Kota SK, JSarangi, Jali SN, Meher LK, Raveendranathan SK. Prevalence of hypothyroidism in patients with metabolic syndrome. \textit{Thyroid Res Pract}. 2013;10(2):60–54.

18. Wang CY, Chang TC, Chen MF. Associations between subclinical thyroid disease and metabolic syndrome. \textit{Endocr J}. 2012;59:911–7.

19. Kim BJ, Kim TY, Koh JM, Kim HK, Park JY, Lee KU, et al. Relationship between serum free T4 (FT4) levels and metabolic syndrome (MS) and its components in healthy euthyroid subjects. \textit{Clin Endocrinol (Oxf)}. 2009;70:152–60.

20. Jayakumar RV. Hypothyroidism and metabolic syndrome. \textit{Thyroid Res Pract}. 2013;10:1–2.

21. Åsvold BO, Bjørk T, Nilsen TIL, Vatten LJ. Association between Blood Pressure and Serum Thyroid-Stimulating Hormone Concentration within the Reference Range: A Population-Based Study. \textit{J Clin Endocrinol Metab}. 2007;92(3):841–5.

22. Fommei E, Iervasi G. The Role of Thyroid Hormone in Blood Pressure Homeostasis: Evidence from Short-Term Hypothyroidism in Humans. \textit{J Clin Endocrinol Metab}. 2002;87(5):1996–2000.

23. Singh BM. Association between insulin resistance and hypothyroidism in females. \textit{Indian J Clin Biochem}. 2010;25(2):141–5.

24. Law A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. \textit{Intern Med}. 1992;231(1):25–30.

25. Bastemir M, Akin F, Alkis E, Kaptanoglu B. Obesity is associated with increased serum TSH level, independent of thyroid function. \textit{Swiss Med Wkly}. 2007;137:431–4.

26. Zimmermann-Belsing T, Brabant G, Holst JJ, Feldt-Rasmussen U. Circulating leptin and thyroid dysfunction. \textit{Eur J Endocrinol}. 2003;149(4):257–71.

27. Lewandowski K, Randeva HS, O’callaghan CJ, Horn R, Medley GF, Hallhouse EW, et al. Effects of insulin and glucocorticoids on the leptin system are mediated through free leptin. \textit{J Intern Med} 2007;156(2):181–6.

28. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willet WC, Rosner BA, et al. Body Fat Distribution and Risk of Non-Insulin-dependent Diabetes Mellitus in Women: The Nurses’ Health Study. \textit{Am J Epidemiol}. 1997;145(7):614–9.
Author biography

Shravya R Ginnaram Student

D Sridevi Associate Professor

Amrut Arvindrao Dambal Professor

Sushritha Y Reddy Student

Abhinav R Pingle Student

Cite this article: Ginnaram SR, Sridevi D, Dambal AA, Reddy SY, Pingle AR. Prevalence of thyroid dysfunction in metabolic syndrome - A cross-sectional study. Int J Clin Biochem Res 2020;7(3):374-379.